Neogen Corp (NEOG) stock
NEOGNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends May 31
Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 7, 2026Score 7/3049% above fair value
$10.55−0.30 (-2.76%)
Close on Nov 20, 2026Market cap $2.30BP/E –Yield –
Neogen net income
Net income is the profit left for shareholders after every expense, interest and tax.
Neogen's net income for the twelve months ending Aug 31, 2026 was -$56.12M. For fiscal 2026 it was -$7.90M. The highest annual figure on record is $63.15M in fiscal 2018.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | May 31, 2026 | -$7.90M | – |
| FY2025 | May 31, 2025 | -$1.09B | – |
| FY2024 | May 31, 2024 | -$9.40M | – |
| FY2023 | May 31, 2023 | -$22.87M | -147.3% |
| FY2022 | May 31, 2022 | $48.31M | -20.7% |
| FY2021 | May 31, 2021 | $60.88M | +2.4% |
| FY2020 | May 31, 2020 | $59.48M | -1.2% |
| FY2019 | May 31, 2019 | $60.18M | -4.7% |
| FY2018 | May 31, 2018 | $63.15M | +44.2% |
| FY2017 | May 31, 2017 | $43.79M | +19.8% |
| FY2016 | May 31, 2016 | $36.56M | +9.1% |
| FY2015 | May 31, 2015 | $33.53M | +19.1% |
| FY2014 | May 31, 2014 | $28.16M | +3.6% |
| FY2013 | May 31, 2013 | $27.19M | +20.8% |
| FY2012 | May 31, 2012 | $22.51M | -1.4% |
| FY2011 | May 31, 2011 | $22.84M | +30.4% |
| FY2010 | May 31, 2010 | $17.52M | – |
Quarterly net income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Aug 31, 2026 | -$11.90M | -132.8% |
| Q4 FY2026CQ2 2026 | May 31, 2026 | -$11.30M | – |
| Q3 FY2026CQ1 2026 | Feb 28, 2026 | -$17.00M | – |
| Q2 FY2026CQ4 2025 | Nov 30, 2025 | -$15.92M | – |
| Q1 FY2026CQ3 2025 | Aug 31, 2025 | $36.30M | – |
| Q4 FY2025CQ2 2025 | May 31, 2025 | -$612.20M | – |
| Q3 FY2025CQ1 2025 | Feb 28, 2025 | -$10.90M | – |
| Q2 FY2025CQ4 2024 | Nov 30, 2024 | -$456.28M | – |
| Q1 FY2025CQ3 2024 | Aug 31, 2024 | -$12.61M | -938.9% |
| Q4 FY2024CQ2 2024 | May 31, 2024 | -$5.39M | -196.8% |
| Q3 FY2024CQ1 2024 | Feb 29, 2024 | -$2.02M | -124.7% |
| Q2 FY2024CQ4 2023 | Nov 30, 2023 | -$3.49M | – |
| Q1 FY2024CQ3 2023 | Aug 31, 2023 | $1.50M | -71.1% |
| Q4 FY2023CQ2 2023 | May 31, 2023 | $5.57M | -62.8% |
| Q3 FY2023CQ1 2023 | Feb 28, 2023 | $8.19M | +50.5% |
| Q2 FY2023CQ4 2022 | Nov 30, 2022 | -$41.84M | -486.4% |
| Q1 FY2023CQ3 2022 | Aug 31, 2022 | $5.21M | -69.5% |
| Q4 FY2022CQ2 2022 | May 31, 2022 | $14.96M | -5.1% |
| Q3 FY2022CQ1 2022 | Feb 28, 2022 | $5.44M | -59.3% |
| Q2 FY2022CQ4 2021 | Nov 30, 2021 | $10.83M | -31.8% |
| Q1 FY2022CQ3 2021 | Aug 31, 2021 | $17.08M | +7.7% |
| Q4 FY2021CQ2 2021 | May 31, 2021 | $15.76M | -3.6% |
| Q3 FY2021CQ1 2021 | Feb 28, 2021 | $13.38M | +9.6% |
| Q2 FY2021CQ4 2020 | Nov 30, 2020 | $15.89M | -2.4% |
| Q1 FY2021CQ3 2020 | Aug 31, 2020 | $15.86M | +8.2% |
| Q4 FY2020CQ2 2020 | May 31, 2020 | $16.35M | +3.4% |
| Q3 FY2020CQ1 2020 | Feb 29, 2020 | $12.20M | -6.7% |
| Q2 FY2020CQ4 2019 | Nov 30, 2019 | $16.28M | +1.4% |
| Q1 FY2020CQ3 2019 | Aug 31, 2019 | $14.65M | -3.8% |
| Q4 FY2019CQ2 2019 | May 31, 2019 | $15.82M | -9.9% |
| Q3 FY2019CQ1 2019 | Feb 28, 2019 | $13.07M | -21.2% |
| Q2 FY2019CQ4 2018 | Nov 30, 2018 | $16.05M | -6.1% |
| Q1 FY2019CQ3 2018 | Aug 31, 2018 | $15.24M | +27.9% |
| Q4 FY2018CQ2 2018 | May 31, 2018 | $17.55M | +40.7% |
| Q3 FY2018CQ1 2018 | Feb 28, 2018 | $16.59M | +61.2% |
| Q2 FY2018CQ4 2017 | Nov 30, 2017 | $17.10M | +53.3% |
| Q1 FY2018CQ3 2017 | Aug 31, 2017 | $11.91M | – |
| Q4 FY2017CQ2 2017 | May 31, 2017 | $12.47M | – |
| Q3 FY2017CQ1 2017 | Feb 28, 2017 | $10.29M | – |
| Q2 FY2017CQ4 2016 | Nov 30, 2016 | $11.15M | – |
See a number that looks wrong?